Rivaroxaban, Anti‑Xa, Plasma
Use
Measurement of rivaroxaban concentration using an anti‑Xa chromogenic assay is useful in select clinical situations such as kidney insufficiency, assessment of compliance, periprocedural drug concentration, suspected overdose, advanced age, and extremes of body weight.
Special Instructions
Not provided.
Limitations
Routine monitoring of rivaroxaban is not indicated; therapeutic reference ranges have not been established. Levels may be affected by drug interactions, liver or kidney disease. The lower limit of detection is 4 ng/mL. Plasma concentrations vary by patient population and dosing schedule, and no interpreted therapeutic ranges are defined in the report.
New York Approved
Methodology
Automated Analyzer (Automated Analyzer)
Biomarkers
Rivaroxaban concentration
Other
LOINC Codes
- 74871-5 - Rivaroxaban PPP Chro-mCnc
- 74871-5 - Rivaroxaban PPP Chro-mCnc
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
1 mL
Minimum Volume
0.5 mL
Container
Light‑blue top (3.2% sodium citrate), plastic vial
Collection Instructions
Collect 2–4 hours post‑dose (peak) or just before next dose (trough). Centrifuge and transfer plasma, centrifuge again, aliquot and freeze immediately (within 4 h). Double‑centrifuged platelet‑poor plasma is required.
Storage Instructions
Freeze immediately; submit frozen plasma.
Causes for Rejection
All specimens evaluated for suitability; thawed, inadequate processing, clotting, incorrect type may lead to rejection.
Stability Requirements
| Temperature | Period |
|---|---|
| Frozen | Frozen: up to 42 days |